Sensorion, the Specialist in Inner Ear Diseases, to Start Human Clinical Trial Phase

Hi,
never heard a lot about this company before.
http://www.businesswire.com/news/ho...Diseases-Completes-Funding-Human#.VL8Kvy6qR-4

http://www.sensorion-pharma.com/

 

Exciting times for us t sufferers. Something good has to come out of all these new medicines.

 

This stems from INSERM, same laboratory who developed models that led to AM101

 

The race to be the first with a legitimate treatment continues.

Sometimes I don't mind living in a capitalist society because since we have such a common condition, tons of companies are jumping over themselves to figure out how to make us satisfied

 

Another article (in French, here for a google translation) about Sensorion.

A clinical trial is planned for a potential treatment for T (phase Ib). Two others programs are on the way for treating inner ear damages related to infection or ototoxic drugs

 

http://www.sensorion-pharma.com/images/20150109-Les_Echos.pdf

Also from this article here, it's specified that it's not "intra tympanic", it may be a pill or intraveinously administered

 

http://www.lesechos.fr/pme-regions/...-loreille-interne-entre-en-bourse-1106594.php

 

Someone that can translate?

 

Sensorion, the expert disorders of the inner ear, goes public
€ 12 million: the objective Sensorion, which launches this morning its IPO on NYSE Alternext , having obtained Friday by the AMF. This "spin off" from INSERM Montpellier, specializing in the treatment of disorders of the inner ear, has "  become a major player in its sector " , summarizes Laurent Nguyen, general manager. "  The potential market is huge: $ 10 billion for 140 million patients  , "he says. "  The business is open and low competition.There is to date no drug treatment for deafness and tinnitus, although it is very debilitating conditions.  "To achieve its ambitious goal Sensorion structured its management with the arrival of two heavyweights health sector: Pierre Attali, a former executive of Sanofi Synthelabo and who took the medical direction of the company, and Patrick Langlois, a former figure of Aventis, which holds the presidency of the board of Directors.

The technology platform is protected by Sensorion 7 patent families. A first drug candidate in clinical trial, is dedicated to acute attacks of vertigo. Two other programs should enter the clinic in 2016, one targeting the complications of active lesions and the other to protect the inner ear against the toxicity of certain drugs, such as chemotherapy. Sensorion, which raised € 10 million since its inception in 2009, has bpifrance's support, through InnoBio, and Inserm Transfert Initiative. Majority before the IPO, the two historical shareholders have pledged to secure the stock transaction at 4.1 million.

http://www.lesechos.fr/pme-regions/...-loreille-interne-entre-en-bourse-1106594.php

 

Good News....we just can hope that one of this conpanies get something on the market....there is still no single drug on the market to do something positive with the inner ear

 

This is really exiting news. This is a new antagonist for Tinnitus going to clinical trials.

The active substances is called SENS-111

Montpellier, France-based Sensorion is swinging for a €12 million ($12.9 million) IPO to finance the advancement of its pipeline of inner ear disease drugs through early and mid-phase clinical trials. Around one-third of the cash is earmarked for a Phase II trial of SENS-111, a histamine H4 receptor antagonist originally developed by Spain's Palau Pharma as a treatment for allergic rhinitis. Sensorion has repurposed the drug as a possible treatment for acute vertigo or tinnitus and advanced it into Phase Ib using up to €4 million it raised from Innobio and Inserm Transfert Initiative in January.

Then they have another one called SENS-218

Sensorion spun out of Inserm--the French public health research institution--in 2009 and set about building a pipeline of drugs for diseases affecting the inner ear. The next drug scheduled to enter Phase II is SENS-218, a drug designed to prevent complications arising from lesions in the inner ear. Sensorion plans to allocate another third of its IPO haul to a Phase II trial of SENS-218, which is expected to get underway in the third quarter of 2016. The rest of the IPO cash will be divvied up between a preclinical program to protect the inner ear following chemotherapy and general tasks.

http://www.fiercebiotech.com/story/parisian-ipo-boomlet-continues-sensorion-setting-terms/2015-03-31

 

Here is a Sensorion presentation from late last year.

 

They seriously need to stop targeting the ear. It's a brain problem, not an ear problem.

 

How many more years will it take for Cure... loosing my life

 

Recent Pat CNS Drug Discov. 2015 Apr 24. [Epub ahead of print]
Histamine H4 Receptor Antagonists: A New Approach for Tinnitus Treatment?
Hagenow J, Stark H1.
Author information
Abstract
Tinnitus, a disorder with disruptive sound perception in the head without an external source, affects around 15 % of the worldwide adult population. Since there is no approved drug for the treatment for this symptom, novel strategies need to be developed to provide relief for the patient. A patent from the small French start-up company Sensorion suggests the use of histamine H4 receptor (H4R) inhibitors as potential treatment. Since histamine and its receptor subtypes are strongly involved in neuronal and inflammatory processes in vestibular areas, targeting the H4R could be a novel way to gain a treatment for tinnitus. Although mRNA and protein levels of H4R have been demonstrated on isolated spiral ganglion neurons from mice, the methods of receptor detection as well as the species relevance of the data are under discussion and require considerable further verification, especially on a disease with a high medical need like tinnitus.
----------------------------------------------------------------------------------------------------------------------------------

This is my first post on this forum. I am interested in the tinnitus research. I have mostly habituated with my tinnitus, but I would be happy to get rid of it.

I noticed this one and wanted to share it. I used pubmed search and this was the newest scientific article http://www.ncbi.nlm.nih.gov/pubmed/25909438.

I really hope that there will be cure for this nasty beast.

Sensorion is a biopharmaceutical company committed to finding targeted and innovative treatments for inner ear disease.

http://www.sensorion-pharma.com/en/

 

Incorrect according to Auris Medical and many other sources. And if AM-101 is approved we have also a solid proof for that.

Of course there is cases when the T has centralized and it becomes "brain problem". The mechanism and timing of T's centralization is yet to be determined.

Anyway, you shouldn't give such a strong statement when most of the information states otherwise.

 

Their website show nothing tinnitus related according to their pipeline :

http://www.sensorion-pharma.com/en/notre-expertise-technologique/pipeline

Also their publications page is all vestibular related.

 

Here is a video presentation of the company:

EnterNext welcomes Sensorion on Alternext in Paris

 

But wait, wouldn't those two ALSO be causes of tinnitus?

 

Ugggg! It seems like scientists are always on the cusp of something but I need a break through for hearing loss and tinnitus. I'm not getting any younger. I guess I should be grateful that work is being done in these areas.